Keith Ward
Sep 11
Kuria Therapeutics Awarded NIH/NEI SBIR Fast Track Phase I/II Grant to Advance IND-Enabling Toxicology Studies of SCO-116 for Corneal Endothelial Disease and Injury
Kuria granted an SBIR award to fund IND-enabling toxicology studies for Fuchs' dystrophy.